3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Stomach Neoplasms
1
Psychological Well-Being
1
Psoriasis
1
Peripheral Nervous System Diseases
1
Osteoarthritis
1
Neoplasms
1
Multiple Myeloma
1
Motor Activity
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cardiovascular Diseases
1
Autoimmune Diseases
1
Arthritis, Rheumatoid
1
Arthralgia
1
Interventions
pembrolizumab
88
Carboplatin
77
Specimen Handling
76
Magnetic Resonance Spectroscopy
63
Pemetrexed
59
Cisplatin
47
durvalumab
44
Paclitaxel
38
Nivolumab
34
atezolizumab
32
osimertinib
29
Radiotherapy
29
Radiosurgery
29
Biopsy
26
Blood Specimen Collection
25
Gemcitabine
24
Docetaxel
24
Immunoglobulin G
23
Disulfides
22
Standard of Care
21
Drug Therapy
21
Etoposide
19
Taxes
18
Practice Guidelines as Topic
18
Radiation
17
Educational Status
16
130-nm albumin-bound paclitaxel
15
X-Rays
14
Surveys and Questionnaires
14
Bevacizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Fish Oils
×
1 year
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled